206 related articles for article (PubMed ID: 27938508)
1. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
[TBL] [Abstract][Full Text] [Related]
2. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
Trials; 2016 Jan; 17():46. PubMed ID: 26811156
[TBL] [Abstract][Full Text] [Related]
4. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M
Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
7. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Manfredi S; Bouché O; Rougier P; Dahan L; Loriot MA; Aparicio T; Etienne PL; Lafargue JP; Lécaille C; Legoux JL; Le Malicot K; Maillard E; Lecomte T; Khemissa F; Breysacher G; Michel P; Mitry E; Bedenne L
Mol Cancer Ther; 2015 Dec; 14(12):2782-8. PubMed ID: 26494856
[TBL] [Abstract][Full Text] [Related]
8. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
[TBL] [Abstract][Full Text] [Related]
9. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
[TBL] [Abstract][Full Text] [Related]
10. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
[TBL] [Abstract][Full Text] [Related]
11. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F
J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727
[TBL] [Abstract][Full Text] [Related]
12. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Okuyama Y; Hazama S; Nozawa H; Kobayashi M; Takahashi K; Fujikawa K; Kato T; Nagata N; Kimura H; Oba K; Sakamoto J; Mishima H
Jpn J Clin Oncol; 2011 Apr; 41(4):477-82. PubMed ID: 21303789
[TBL] [Abstract][Full Text] [Related]
13. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Yeh YS; Huang ML; Chang SF; Chen CF; Hu HM; Wang JY
Med Princ Pract; 2014; 23(5):478-81. PubMed ID: 24642571
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping.
Lu CY; Yeh YS; Huang CW; Ma CJ; Yu FJ; Wang JY
Onco Targets Ther; 2014; 7():2143-6. PubMed ID: 25473295
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Suenaga M; Fuse N; Yamaguchi T; Yamanaka Y; Motomura S; Matsumoto H; Hamamoto Y; Mizunuma N; Doi T; Hatake K; Iwasaki J; Ohtsu A
J Clin Pharmacol; 2014 May; 54(5):495-502. PubMed ID: 24382596
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]